A multinational study led by Chinese University of Hong Kong researchers found that D3S-001, a mainland-developed cancer drug, effectively treats tumors driven by KRAS-G12C gene mutations.
D3S-001 demonstrated a 73.5% overall response rate in KRAS G12C inhibitor-naïve patients across multiple tumor types, including impressive efficacy in colorectal cancer (88.9%) and pancreatic cancer (75.0%).
A multinational study led by Chinese University researchers found that D3S-001, a mainland-developed KRAS-G12C inhibitor, demonstrated significant efficacy with over 70% of patients experiencing tumor shrinkage or disappearance.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.